An endogenous antioxidant anti-wrinkle composition, its preparation method and use

Abstract

The present application relates to the field of cosmetics, in particular to an endogenous antioxidant anti-wrinkle composition, a preparation method and application thereof, the composition comprises acetyl tetrapeptide-5, CycloRetin, collagen type 21, acetyl hexapeptide-8 and vitisins, the composition can promote the synthesis of collagen in the extracellular matrix of the dermis of the skin, and can improve the tightening and anti-wrinkle effect, human test proves that the tightening and anti-wrinkle effect of the composition is the best.

Description

Technical Field

[0001] This invention relates to the field of cosmetics, and more specifically to an antioxidant and anti-wrinkle composition, its preparation method, and its application. Background Technology

[0002] As we age, cell metabolism slows down, and the balance between cell proliferation and differentiation and cell aging and apoptosis becomes unbalanced. This leads to a decreased ability of aging cells to eliminate free radicals in the body. In addition, continuous exposure to the external environment, including respiration, ultraviolet radiation, and electromagnetic radiation, constantly generates free radicals in the body. Excessive free radicals attack cellular DNA, causing cell damage and oxidizing unsaturated fatty acids in the skin's lipid layer. This produces lipofuscin, a marker of cellular aging, which accumulates within cells, leading to skin aging, wrinkles, age spots, and decreased elasticity.

[0003] With the development of the modern economy and the increasing awareness of skincare, as well as the pursuit of beautiful skin quality, people are taking care of their skin more frequently. When choosing skincare products, in addition to seeking natural, gentle, and safe options, people also require that the selected skincare products achieve good results.

[0004] Currently, the effects of cosmetic ingredients on the market are often relatively singular, and there is a frequent problem that when multiple cosmetic ingredients are combined, their effects become worse.

[0005] Acetyl hexapeptide-8 (amino acid sequence: Ac-EEMQRR-NH2) is a safe and gentle alternative to botulinum toxin that can reduce wrinkles caused by facial muscle contractions in a short period of time, especially wrinkles around the eyes, forehead, and corners of the mouth, such as crow's feet, nasolabial folds, and marionette lines.

[0006] Acetyl tetrapeptide-5 (amino acid sequence: Ac-β-AHSH) enhances the activity of antioxidant enzymes, prevents cross-linking between collagens, inhibits collagen glycation, improves skin elasticity, and plays an anti-aging role.

[0007] CycloRetin, also known as Codonopsis pilosula cyclic peptide (amino acid sequence: It is a new type of anti-aging ingredient that stimulates the production of collagen and skin structure compounds, increases skin density, and thus plumps the skin from the inside out.

[0008] Type 21 collagen is a recombinant collagen prepared through biotechnology. Its main functions are to improve skin elasticity, promote repair, improve skin texture, and help delay aging. It mimics the structure of the body's own collagen, helping to fill the skin's internal support structure while stimulating the body's own collagen regeneration, thus improving fine lines and firming the skin. CN202111264263.X discloses a recombinant humanized collagen and its preparation method, and also discloses the specific amino acid sequence.

[0009] The amino acid sequence is as follows:

[0010] .

[0011] MitoVitalin®253 is a newly launched ingredient from the Huibai Research Institute. Its main components are Artemia extract, ribose, and trisodium fructose diphosphate, a combination of three major ATP energy-replenishing factors that enhance cellular energy, stimulate the production of more collagen, and promote epidermal regeneration to rejuvenate the skin.

[0012] CycloRetin increases SPARC in the dermis, enhances the synthesis of type I and type III collagen, improves dermal structure, and reduces oxidative damage and skin aging caused by oxidative stress. Acetyl hexapeptide-8 inhibits the transmission of nerve signals in the skin, suppressing dynamic wrinkles. Type 21 collagen stimulates the production of collagenase, reduces collagen degradation, and increases collagen content. Acetyl tetrapeptide-5 enhances the activity of antioxidant enzymes and prevents cross-linking between proteins. Vitalin boosts cellular energy and stimulates the production of more collagen. The combination of these five active ingredients with different anti-wrinkle mechanisms works synergistically from different dimensions to truly improve dermal structure and greatly enhance anti-aging effects.

[0013] Therefore, it is necessary to develop an active composition containing multiple anti-wrinkle mechanisms to synergistically enhance the antioxidant and anti-wrinkle care product. Summary of the Invention

[0014] In view of the above situation, the present invention provides an endogenous antioxidant and anti-wrinkle composition, the composition comprising: acetyl tetrapeptide-5, CycloRetin, type 21 collagen, acetyl hexapeptide-8 and vitamin.

[0015] In this invention, as one embodiment, the content of acetyl tetrapeptide-5 is 0.005~0.01wt% by weight of the composition; the content of CycloRetin is 0.1~1wt%; the content of type 21 collagen is 0.01~0.1wt%; the content of acetyl hexapeptide-8 is 0.005~0.1wt%; and the content of vitamin is 0.5~5%.

[0016] In this invention, as one embodiment, the composition comprises: 0.01 wt% acetyl tetrapeptide-5; 0.3 wt% CycloRetin; 0.01 wt% type 21 collagen; 0.01 wt% acetyl hexapeptide-8; and 2.0 wt% vitamin, based on the weight of the composition.

[0017] In this invention, as one embodiment, the endogenous antioxidant and anti-wrinkle composition is in the form of a skin care product, which is selected from toner, face cream, eye cream, serum, or mask.

[0018] On the other hand, the present invention also provides a skin care product. In this invention, as one embodiment, the skin care product includes group A, group B or group C, or a combination of two or three of them.

[0019] As one implementation scheme, the skincare product includes component group C, or may also include component group A and / or component group B; wherein,

[0020]

[0021] In this invention, as one embodiment, the skincare product comprises a combination of component group A, component group B, and component group C; wherein,

[0022]

[0023] In this invention, as one embodiment, the skincare product includes:

[0024]

[0025] The present invention also provides a method for preparing the skin care product described above, the method comprising:

[0026] 1) Add deionized water, 3-butanediol, glycerol, p-hydroxyacetophenone, carbomer U20, and Aristoflex AVC to the aqueous phase pot, stir for 10-20 minutes, homogenize for 5 minutes, and heat to 85-95℃ to obtain aqueous phase A.

[0027] 2) Add MONTANOV 202, hydrogenated lecithin, polydimethylsiloxane, Skycore PT028, cetyl ethylhexanoate, and jojoba oil to an oil pan, stir for 10-20 minutes, and heat to 85-95℃ to obtain phase B of the oil phase material;

[0028] 3) The oil phase material B is drawn into the emulsification pot through a filtration device; the aqueous phase material A is drawn into the emulsification pot containing the oil phase material B through a filtration device, and stirred at high speed until uniform. Then, it is homogenized at a rate of 3000-3500 rpm for 5-10 minutes to obtain a mixture. The mixture is stirred and cooled, vacuumed, and cooled to 45℃. Then, component C is added and stirred for 10-20 minutes, homogenized for another 3-5 minutes, filtered, discharged, and inspected to obtain the cosmetic composition.

[0029] In this invention, as one embodiment, the method includes: Group C components include 1,2-hexanediol, Mycopurulent, acetyl tetrapeptide-5, type 21 collagen, CycloRetin, acetyl hexapeptide-8, vitamin, hexaglycoside, arginine, centella asiatica hydrosol, and SymCalmin PLUS.

[0030] The present invention also provides the use of an endogenous antioxidant and anti-wrinkle composition or skin care product in the preparation of cosmetics with anti-wrinkle, anti-aging, anti-dark circle, or antioxidant properties.

[0031] This invention achieves a synergistic effect through the coordinated action of its various components, improving the dermal structure from different dimensions. It increases SPARC in the dermis, thereby enhancing the synthesis of type I and type III collagen in the dermis. At the same time, it inhibits the transmission of skin nerve signals and the activity of collagenase, promoting collagen production. Thus, it achieves multi-dimensional and truly effective protection of the dermal structure, greatly improving the anti-aging effect.

[0032] The experimental results show that by rationally selecting raw materials and their dosages, and by confirming through cell testing that the various active ingredients have a synergistic effect, the anti-aging eye cream of this invention can promote the synthesis of collagen in the extracellular matrix of the dermis, thereby enhancing its firming and anti-wrinkle effects. Human trials have confirmed that the eye cream invented by benzene has the best firming and anti-wrinkle effects. Attached Figure Description

[0033] Figure 1 The expression results of type I and type III collagen in compositions 1-3 and control compositions 1-5 in Experimental Example 2. Detailed Implementation

[0034] The present invention will be further illustrated by the following embodiments, comparative examples and experimental examples, but the scope of protection of the present invention is not limited thereto.

[0035] Example 1: Preparation of compositions 1-3 and comparative compositions 1-5

[0036] 1.1 Component types and proportions

[0037] The types and proportions (wt%) of components of compositions 1-3 and comparative compositions 1-5 are shown in Table 1.

[0038] Table 1

[0039]

[0040] 1.2 Preparation method

[0041] Compositions 1-3 and comparative compositions 1-5 are shown in Table 1 (Note: the proportions of each component are different), and their preparation methods include the following steps:

[0042] Add the active ingredient to water and stir for 30 minutes until completely dissolved.

[0043] Experimental Example 1: In vitro cell assays for screening different components and concentrations:

[0044] Sample and reagent sources: Fetal bovine serum (Gibco); DMEM-high glucose medium (Gibco); trypsin (Gibco); RIPA lysis buffer (Beyotime Biotechnology); ROS kit (Beyotime Biotechnology); BCA kit (Nanjing Jiancheng Biotechnology Institute).

[0045] 1.1 ROS (Reactive Oxygen Species) Content in Human Skin Fibroblasts (HSF)

[0046] HSF cells were seeded and cultured until adherent. The culture medium was discarded, and the cells were washed with PBS. Serum-free medium containing 400 µM H₂O₂ was added, and the cells were incubated at 37°C for 30 min to establish an oxidative damage model. The control group did not undergo hydrogen peroxide modeling. The supernatant was discarded, and the cells were washed twice with PBS. The experimental sample was added, and the cells were cultured for another 24 h. The supernatant was discarded, and 10 µM DCFH-DA serum-free diluent was added. The cells were incubated in the dark for 30 min. The cells were washed three times with serum-free DMEM to thoroughly remove any probes that had not entered the cells. The cells were digested with trypsin, and the cell suspension was transferred to 96-well cells with black borders. Fluorescence intensity was measured at 488 nm excitation and 525 nm emission wavelengths using a microplate reader to determine the relative ROS content.

[0047] Table 2. Effects of samples on H2O2-induced intracellular ROS levels in human skin fibroblasts.

[0048]

[0049] Note: In cell experiments, a reduction of ROS value ≥30% was considered effective; a reduction ≥40% was considered relatively potent; and a reduction ≥50% was considered highly potent. Experimental results showed that the combination of 0.3% CycloRetin and 0.01% type 21 collagen in reducing H2O2-induced intracellular ROS levels in human skin fibroblasts had a synergistic effect, exhibiting good antioxidant and anti-wrinkle effects.

[0050] 1.2 Superoxide dismutase (SOD) activity in human skin fibroblasts (HSF):

[0051] Cell resuscitation and passage were performed. Cells were then subjected to UVA irradiation and divided into control, model, and sample groups. Control group: cells were cultured in normal medium without UVA irradiation. Model and sample groups: before UVA irradiation, the culture medium was aspirated, the cells were washed once with PBS, and a small amount of PBS was added to cover the upper layer of cells before irradiation with UVA at a dose of 10 J / cm². 2 After irradiation, the PBS was removed. The model group was added with culture medium without the test sample, and the sample group was added with culture medium containing the test sample. The cells were cultured for another 24 hours to obtain cell culture supernatant or cells for subsequent experiments.

[0052] After HSF cell irradiation, add 2 mL of each sample listed in Table 4 and continue incubation for 24 h. Then, aspirate the supernatant and add 300 μL of lysis buffer per well to a six-well plate to cover the cells. Incubate for 30 min and gently pipette to collect the cell lysate for analysis.

[0053] Bicinchoninic Acid (BCA) method for determining protein content

[0054] Add 0, 1, 2, 4, 8, 16, and 20 μL of the standard to a 96-well plate. For wells with less than 20 μL, make up the volume to 20 μL with sterile water.

[0055] Add 200 μL of BCA working solution to each well and react at 37 °C for 30 min.

[0056] The OD value at 570 nm was measured using an ELISA reader, a standard curve was plotted, and the OD value of the sample was measured using the same method to determine the concentration of the sample to be tested.

[0057] Prepare the standard and test samples according to Table 3. After adding the samples, mix them well and incubate at 37°C for 20 min. Then, use an ELISA reader to measure the absorbance at a wavelength of 450 nm.

[0058] Table 3. Sample dosing formulation for superoxide dismutase (SOD) activity assay (unit: μL)

[0059]

[0060] SOD inhibition rate (%) = [A control - A blank control] - (A assay - A blank control) / (A control - A blank control) * 100%

[0061] SOD activity (NU / mgprot) = (SOD inhibition rate × reaction system) / (50% x test sample dilution factor × test sample protein concentration)

[0062] The test results are as follows:

[0063] Table 4. Effects of samples on SOD activity in cells after UVA irradiation (n=3, )

[0064]

[0065] The experimental results showed that at the cellular level, the combination of 0.01% acetyl tetrapeptide-5+ and 0.01% CycloRetin had the strongest synergistic effect in enhancing SOD activity in cells irradiated by UVA, and exhibited good antioxidant properties.

[0066] Experimental Example 2: Detection of the expression levels of type I and type III collagen using enzyme-linked immunosorbent assay (ELISA).

[0067] Sample and reagent sources: Human type I collagen ELISA kit (RD Company); Human type III collagen ELISA kit (RD Company)

[0068] Compositions 1-3 and control compositions 1-5 were used to detect the expression levels of type I and type III collagen.

[0069] Human fibroblast resuscitation: Preheat the water bath to 37 ℃; wipe the surface of the laminar flow hood, which has been irradiated with ultraviolet light for 30 min, with 75% alcohol; arrange sterilized centrifuge tubes, pipettes, culture flasks, etc. in the laminar flow hood in order; remove the cryovials and quickly immerse them in the preheated water bath to thaw, shaking continuously to rapidly melt the liquid in the tubes; wipe the outer wall of the cryovials with an alcohol swab and then place them back into the laminar flow hood; prepare the cell suspension by transferring the cells to centrifuge tubes, adding preheated culture medium while shaking the centrifuge tubes; centrifuge at 1000 rpm for 5 min on a low-speed centrifuge, aspirate the supernatant, and then resuspend the cells in 1 mL of culture medium; aliquot the cell suspension into culture dishes and place the culture dishes in a CO2 incubator at 37 ℃ for culture; the frequency of medium changes depends on the cell adhesion.

[0070] Subculturing: Remove the cell culture flask, open the cap, and aspirate the old culture medium; wash the cells twice with PBS; add trypsin-EDTA solution (1 mL / 25 cm⁻¹). 2 2 mL / 75 cm 2 Clean the bottom of the cell culture dish. Aspirate the trypsin-EDTA solution and incubate at 37 ℃ for 2-3 min. Observe under an inverted microscope. When the cells are about to separate and appear granular, add an appropriate amount of fresh culture medium containing serum to stop the trypsin effect. Use a pipette to aspirate and dissipate several times to break up the cell clumps. After mixing evenly, add 3n (n is the number of passage bottles) mL of culture medium (DMEM) and transfer to new culture bottles according to the dilution ratio. Place in a CO2 incubator (culture conditions: 37 ℃, 5% CO2 and saturated humidity).

[0071] Sample preparation: Take 1g of sample, add 9mL of complete culture medium, vortex for 15min, sonicate for 30min, centrifuge at 5000rpm for 10min, collect the supernatant, and discard the precipitate / oil layer. The supernatant is the 10% stock solution, which is sterilized by filtration through a 0.22µm filter membrane. Dilute 10 times with complete culture medium to obtain the sample.

[0072] Experimental Groups: Cells were divided into a control group, a model group, and a sample group. Control group: Cells were cultured in normal medium without UVA irradiation. Model group and sample group: Cells were pre-incubated with 100 ng / mL 8-MOP for 24 h. Before UVA irradiation, the culture medium was aspirated, the cells were washed once with PBS, and then a small amount of PBS was added to cover the upper layer of cells before irradiation with UVA at a dose of 10 J / cm². 2 .

[0073] ELISA Assay: Perform triple replicates for each standard and blank well. Add 50 µL of diluted standard to each well, followed by 50 µL of cell supernatant from each group to be tested. Immediately add 50 µL of biotin-labeled antibody. Cover the plate, gently vortex to mix, and incubate at 37 °C for 1 h. Discard the liquid from the wells, fill each well with washing buffer, and vortex for 30 s. Discard the washing buffer and pat dry with absorbent paper. Repeat this process 3 times. If using a plate washer, increase the number of washes by one. Add 60 µL of streptavidin-HRP to each well, gently vortex to mix, and incubate at 37 °C for 30 min. Discard the liquid from the wells, fill each well with washing buffer, and vortex for 30 s. Discard the washing buffer and pat dry with absorbent paper. Repeat this process 3 times. Add 50 µL each of substrate A and B to each well, gently vortex to mix, and incubate at 37 °C for 10 min. Avoid light exposure. Remove the ELISA plate and quickly add 50 µL of stop solution. The results should be measured immediately after adding the stop solution. Using an ELISA reader, measure the OD value of each well at 450 nm. Plot standard curves for type I and type III collagen and calculate the concentration of each sample.

[0074] The test results are shown in Table 5 below. Figure 1 :

[0075] Table 5. Expression levels of type I and type III collagen in compositions 1-3 and control compositions 1-5 (n=3, )

[0076]

[0077] The experimental results showed that at the cellular level, composition 1 could restore type I and type III collagen to normal levels; changing the amount of each major component (compositions 2 and 3), or reducing one of the major components (comparative compositions 1 to 5), did not have good results.

[0078] Experiment Example 3: Human Efficacy Test

[0079] Eye Cream 1: Add Composition 1 to the eye cream to obtain Eye Cream 1. The ingredients and formulation of Eye Cream 1 are shown in Table 6 below:

[0080] Table 6. Ingredients and proportions of Eye Cream 1

[0081]

[0082] Eye Cream 2: Replace composition 1 in eye cream 1 with composition 2 to obtain eye cream 2;

[0083] Eye Cream 3: Replace composition 1 in eye cream 1 with composition 3 to obtain eye cream 3;

[0084] Eye Cream 4: Remove composition 1 from Eye Cream 1 to obtain Eye Cream 4.

[0085] The preparation methods for eye creams 1-4 above are as follows:

[0086] Add deionized water, 3-butanediol, glycerol, p-hydroxyacetophenone, carbomer U20, and Aristoflex AVC to an aqueous phase pot, stir for 10-20 minutes, homogenize for 5 minutes, and heat to 85-95℃ to obtain aqueous phase A.

[0087] Add MONTANOV 202, hydrogenated lecithin, polydimethylsiloxane, Skycore PT028, cetyl ethylhexanoate, and jojoba oil to an oil pan, stir for 10-20 minutes, and heat to 85-95℃ to obtain phase B of the oil phase material;

[0088] The oil phase material B is drawn into the emulsification pot through a filtration device; the aqueous phase material A is drawn into the emulsification pot containing the oil phase material B through a filtration device, and stirred at high speed until uniform. Then, it is homogenized at a rate of 3000-3500 rpm for 5-10 minutes to obtain a mixture. The mixture is stirred and cooled, vacuumed, and cooled to 45°C. Then, the C group material is added, stirred for 10-20 minutes, homogenized for another 3-5 minutes, filtered, discharged, and inspected to obtain the cosmetic composition.

[0089] The C group of materials includes 1,2-hexanediol, Mizopurin, acetyl tetrapeptide-5, type 21 collagen, CycloRetin, acetyl hexapeptide-8, vesinolide, hexaglycoside, arginine, centella asiatica hydrosol, and SymCalmin PLUS (Note: The composition of C group varies depending on the composition of C group 1 to 3).

[0090] Among them, Miaochunka is a brand name, sourced from Suzhou Nakang Biotechnology Co., Ltd.; Weiliyin is a complex of multiple ingredients, a commercially available raw material from Huibai Research Institute; Carbomer U20 is from Lubrizol and is used as a thickener; Aristoflex AVC is from Guangzhou Aoxue Chemical and is used as a thickener; MONTANOV 202 is from Guangzhou Baihaobo and is used as an emulsifier; Skycore PT028 is from Zhonghaojing and is used as a skin feel modifier; SymCalmin PLUS is a commercially available raw material from Symrise.

[0091] (1) Instruments and Samples

[0092] Instruments: VISIA CR (Canfield); FrameScan33 skin comprehensive analysis software.

[0093] Test samples: Skin care product composition samples prepared in Examples 1-3.

[0094] (2) Subjects

[0095] Qualified volunteers were selected and signed informed consent forms to ensure that 30 people were ultimately selected, with 10 people participating in the trial of each sample.

[0096] Inclusion criteria: Healthy female volunteers aged 30-45 with a daily skincare routine; volunteers had fine lines / wrinkles around the eyes and were not sensitive to commonly used cosmetics; participants had high compliance.

[0097] Exclusion criteria: Individuals who have used antihistamines within the past week or immunosuppressants within the past month; individuals who have used any anti-inflammatory drugs on the test site within the past two months; insulin-dependent diabetic patients; patients currently receiving treatment for respiratory diseases; individuals with allergies, allergic dermatitis, or a history of skin diseases; individuals currently receiving dermatological treatment or who have taken amino acid-based, whitening, or anti-aging drugs within the past month; individuals with large areas of birthmarks, scratches, vitiligo, pigmented nevi, scars, bumps, or other skin characteristics that may affect the test.

[0098] (3) Test environment conditions: The test environment temperature is 20-22℃ and the humidity is 40-60%, and real-time dynamic monitoring is carried out.

[0099] (4) Product usage method: 2 times / day (once in the morning and once in the evening). During the test, subjects should avoid excessive exposure to ultraviolet light.

[0100] (5) Testing process

[0101] Before and 4 weeks after sample use, the subjects washed their faces with a facial cleanser and sat quietly in a temperature- and humidity-controlled room for 30 minutes before having their faces photographed using VISIA CR. Images of the subjects' faces were acquired using a VC20Plus, and changes in the number and depth of wrinkles around the eyes were analyzed.

[0102] Table 6 Instrument test results (Number of test participants: 10 people per group)

[0103]

[0104] Human efficacy testing results show that Eye Cream 1 has the best anti-wrinkle and firming effect, and the combination ratio of various active ingredients in Eye Cream 1 is the best.

[0105] The above results show that: by rationally selecting raw materials and their dosages, and by confirming through cell testing that the various active ingredients have a synergistic effect, the anti-aging eye cream of this invention can promote the synthesis of collagen in the extracellular matrix of the dermis, thereby enhancing its firming and anti-wrinkle effects; and by confirming through human trials that the eye cream invented by benzene has the best firming and anti-wrinkle effects.

Claims

1. An endogenous antioxidant and anti-wrinkle composition, characterized in that, The composition comprises: acetyl tetrapeptide-5, CycloRetin, type 21 collagen, acetyl hexapeptide-8, and veligin.

2. The endogenous antioxidant and anti-wrinkle composition according to claim 1, characterized in that, Based on the weight of the composition, the content of acetyl tetrapeptide-5 is 0.005~0.01wt%; the content of CycloRetin is 0.1~1wt%; the content of type 21 collagen is 0.01~0.1wt%; the content of acetyl hexapeptide-8 is 0.005~0.1wt%; and the content of vitamin is 0.5~5%.

3. The endogenous antioxidant and anti-wrinkle composition according to claim 1, characterized in that, The composition comprises, by weight of the composition, 0.01 wt% acetyl tetrapeptide-5; 0.3 wt% cycloRetin; 0.01 wt% type 21 collagen; 0.01 wt% acetyl hexapeptide-8; and 2.0 wt% virginin.

4. The endogenous antioxidant and anti-wrinkle composition according to any one of claims 1 to 3, characterized in that, The composition is in the form of a skin care product, which is selected from toners, face creams, eye creams, serums, or face masks.

5. A skincare product, characterized in that, The skincare product may include component group C, or may also include component group A and / or component group B. in: 。 6. The skincare product according to claim 5, characterized in that, The skincare product comprises component group C, component group A, and component group B, wherein: 。 7. The skincare product according to claim 6, characterized in that, The skincare products include: 。 8. A method for preparing a skincare product according to any one of claims 5 to 7, characterized in that, The method includes: 1) Add deionized water, 3-butanediol, glycerol, p-hydroxyacetophenone, carbomer U20, and Aristoflex AVC to the aqueous phase pot, stir for 10-20 minutes, homogenize for 5 minutes, and heat to 85-95℃ to obtain aqueous phase A. 2) Add MONTANOV 202, hydrogenated lecithin, polydimethylsiloxane, Skycore PT028, cetyl ethylhexanoate, and jojoba oil to an oil pan, stir for 10-20 minutes, and heat to 85-95℃ to obtain phase B of the oil phase material; 3) The oil phase material B is drawn into the emulsification pot through a filtration device; the aqueous phase material A is drawn into the emulsification pot containing the oil phase material B through a filtration device, and stirred at high speed until uniform. Then, it is homogenized at a rate of 3000-3500 rpm for 5-10 minutes to obtain a mixture. The mixture is stirred and cooled, vacuumed, and cooled to 45℃. Then, component C is added and stirred for 10-20 minutes, homogenized for another 3-5 minutes, filtered, discharged, and inspected to obtain the cosmetic composition.

9. The method for preparing the skincare product according to claim 8, characterized in that, The method includes: The C group components include 1,2-hexanediol, Mizopuric acid, acetyl tetrapeptide-5, type 21 collagen, CycloRetin, acetyl hexapeptide-8, vesinolide, hexaglycoside, arginine, centella asiatica hydrosol, and SymCalmin PLUS.

10. The use of the endogenous antioxidant and anti-wrinkle composition according to any one of claims 1 to 4, or the skin care product prepared by any one of claims 5 to 7 or any one of claims 8 to 9, in the preparation of anti-wrinkle, anti-aging, anti-dark circle, and antioxidant cosmetics.

Images